dc.contributor.author | Guthmann, Richard | eng |
dc.contributor.author | Bahrami, Azita | eng |
dc.contributor.author | Martin, Robert | eng |
dc.contributor.author | Nashelsky, Joan | eng |
dc.date.issued | 2019 | eng |
dc.description.abstract | Q Do A-fib patients continue to benefit from vitamin K antagonists with advancing age? Evidence-based answer: yes, patients with atrial fibrillation who are between the ages of 50 and 90 years continue to benefit from vitamin K antagonist therapy (warfarin) (strength of recommendation [SOR]: A, meta-analysis of randomized controlled trials [RCTs] and large cohorts). Regardless of age, warfarin produces a reduction in risk of thrombotic events that is 2- to 4-fold greater than the risk of hemorrhagic events. | eng |
dc.description.bibref | Includes bibliographical references | eng |
dc.description.sponsorship | Richard Guthmann, MD, MPH; Azita Bahrami, DO; Robert Martin, DO, Advocate Illinois Masonic Family Medicine Residency, Chicago ; Joan Nashelsky, MLS, Family Physicians Inquiries Network, Columbia, Mo | eng |
dc.format.extent | 3 pages | eng |
dc.identifier.uri | https://hdl.handle.net/10355/69682 | eng |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Clinical Inquiries, 2019 (MU) | eng |
dc.relation.ispartofcommunity | University of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network | eng |
dc.relation.ispartofseries | Journal of family practice, 68, no. 06 (July/August 2019): p. 0E12-E14 | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.title | Do A-fib patients continue to benefit from vitamin K antagonists with advancing age? | eng |
dc.type | Article | eng |